KCNB1 and epilepsy: De novo heterozygous mutations of KCNB1 result in a variety of functional defects, such as loss of ion selectivity, reduced conductance, and dominant adverse effects (28), clinically leading to neurodevelopmental disorders, autism spectrum disorder, and epilepsy of variable severity as reported (27).